Opinion|Videos|May 28, 2024
Long-Term Outcomes for Patients Treated for Hypercortisolism
The panel concludes by discussing the long-term outcomes for patients treated for hypercortisolism, emphasizing the need for further studies and data, and sharing their final thoughts on the disease and its future management.
Advertisement
Episodes in this series
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
Advances in Treating High-Impact Psoriasis from EADV 2026
3
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines to Include HYPERION Data
4
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
5